(Q33216260)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

Rosamonde Elizabeth Banks

12 January 2020

main subject

phase I clinical trial

0 references

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Adrian Harris

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Ord JJ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Streeter E

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Jones A

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Le Monnier K

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Cranston D

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Crew J

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Joel SP

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Rogers MA

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Roberts IS

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

2140-2147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602650

12 January 2020

exact match

0 references

cites work

Oligoclonality in bladder cancer: the implication for molecular therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Vascular endothelial growth factor as a marker of tumor endothelium.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Acute renal toxicity associated with suramin in the treatment of prostate cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Suramin binds to platelet-derived growth factor and inhibits its biological activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin. Implications for the mechanism of autocrine transformation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: Binding, internalization, degradation, and biological effects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Cell transformation by kFGF requires secretion but not glycosylation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

Suramin: With Special Reference to Onchocerciasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361814

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602650

Intravesical suramin in the prevention of transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602650

Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602650

URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602650

Suramin is a Potent Inhibitor of Vascular Endothelial Growth Factor. A Contribution to the Molecular Basis of its Antiangiogenic Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602650

Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures

21 January 2018

1 reference

12 December 2020

Different angiogenic pathways characterize superficial and invasive bladder cancer

1 reference

12 December 2020

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up

1 reference

12 December 2020

Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer

1 reference

12 December 2020

Investigation of suramin-albumin binding by electrospray mass spectrometry

1 reference

12 December 2020

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602650

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 January 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15928663%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference